首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1542928

全球 HDL 胆固醇试剂盒市场 - 2024-2031

Global HDL Cholesterol Kits Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

2023年，全球HDL胆固醇试剂盒市场规模达到6.4702亿美元，预计2031年将达到10.0568亿美元，2024-2031年预测期间复合年增长率为5.8%。

血浆脂蛋白包括许多主要类型，其中之一是高密度脂蛋白（HDL）。它们的大小、脂质和载脂蛋白含量各不相同，由许多异质颗粒组成，包括胆固醇。高密度脂蛋白负责将胆固醇从週边细胞转移到肝臟，在那里转化为胆汁酸并透过肠道消除。

HDL-C 的精确评估对于确定患者罹患冠心病的风险至关重要。当使用直接测量代替沉淀技术时，准确性和可重复性会提高。通常，高密度脂蛋白与其他测试一起进行，例如胆固醇或血脂谱（包括三酸甘油酯和低密度脂蛋白）的测试。高密度脂蛋白和总胆固醇一起是心臟病风险非常有用的筛检工具。

市场动态：

司机

心血管疾病盛行率上升

随着全球人口特别是老年人口的增长，中风、动脉粥状硬化、冠状动脉疾病和心臟病等心血管疾病的发生率预计也会上升，对医疗干预产生巨大的需求。根据联合国统计，到2030年，全球人口预计将达到85亿，2050年将达97亿。根据世界卫生组织（WHO）估计，2030年60岁以上老年人口将接近14亿，2050年将达21亿。

大多数心血管疾病的罪魁祸首是低密度脂蛋白（LDL）、极低密度脂蛋白（VLDL）、三酸甘油酯和胆固醇。这些物质的累积会导致身体各部位的血液循环受阻，进而导致严重的疾病。高密度脂蛋白（HDL），也称为好胆固醇，已知可以降低坏胆固醇的水平，尤其是低密度脂蛋白。这种高密度脂蛋白有助于分解在血管中形成血栓的低密度脂蛋白，并将其运回肝臟，低密度脂蛋白在肝臟中被隔离并从体内消除或以脂质细胞的形式储存。

HDL-C 测试是为了评估患者的心血管健康状况，包括心臟病的风险。好胆固醇（HDL-C）与降低冠心病事件的风险有关。医生可以透过测量相同血液样本中的总胆固醇和 HDL-C 轻鬆计算 HDL-C 与非 HDL 胆固醇的比率，这对于评估患者的心血管健康至关重要。

现代世界人口老化、久坐的生活方式和饮食习惯的改变预计将增加心血管疾病的发病风险。

例如，美国心臟协会指出，全球约有 1,800 万人死于心血管疾病 (CVD)，高收入国家和低收入国家 (HIC) 以及中低收入国家之间存在显着差异。中低收入国家在全球心血管疾病 (CVD) 负担中所占比例过高，占全球所有心血管疾病死亡人数的 80%。

此外，根据澳洲国家心臟基金会的数据，六分之一的澳洲人患有心血管疾病，病例数接近 450 万，占澳洲总人口的 18%。此外，澳洲有超过 1500 例住院病例和 24% 的死亡病例是由 CVD 造成的。

随着这一趋势预计将上升，对预防性健康措施的需求预计将增加，其中包括及时的心臟健康监测，预计将在预测期内对高密度脂蛋白胆固醇检测试剂盒产生巨大的需求。

限制

高密度脂蛋白胆固醇试剂盒的高成本是可能阻碍市场成长的限制因素之一。对于营运预算较低的小型卫生中心和诊所来说，这可能是一种经济负担。此外，患者尤其是生活在农村地区的患者对定期胆固醇检查的重要性缺乏认识是可能限制市场成长的另一个因素。

Market Overview

The Global HDL Cholesterol Kits Market reached US$ 647.02 million in 2023 and is expected to reach US$ 1,005.68 million by 2031, growing at a CAGR of 5.8% during the forecast period 2024-2031.

Plasma lipoproteins include many primary types, one of which is high-density lipoproteins (HDL). They vary in size and lipid and apolipoprotein content and are made up of many heterogeneous particles, including cholesterol. HDL is responsible for transferring cholesterol from peripheral cells to the liver, where it is transformed into bile acids and eliminated through the intestines.

Precise evaluation of HDL-C is essential for determining a patient's risk of coronary heart disease. When direct measurement is used instead of precipitation techniques, accuracy and repeatability are increased. Typically, HDL is ordered in conjunction with additional tests, such as those for cholesterol or lipid profiles that include triglycerides and LDL. HDL and total cholesterol together are a highly helpful screening tool for heart disease risk.

Market Dynamics: Drivers

Rising prevalence of cardiovascular conditions

As the global population is rising especially the old-age demographic, the incidence of cardiovascular conditions such as stroke, atherosclerosis, coronary artery disease, and heart attack are also expected to rise, creating a huge demand for medical intervention. As per the United Nations statistics, by 2030, the global population is predicted to reach 8.5 billion and in 2050 to 9.7 billion. As per the World Health Organization (WHO) estimates, the old-age population above 60 years would be nearly 1.4 billion in 2030 and 2.1 billion in 2050.

The major culprit behind majority of the cardiovascular conditions is low-density lipoprotein (LDL), very low-density lipoproteins (VLDL), triglycerides, and cholesterol. Accumulation of these will lead to blockage of blood circulation to various parts of the body that results in serious morbid conditions. The high-density lipoprotein (HDL), also known as good cholesterol, is known to reduce the levels of bad cholesterol, especially LDL. This HDL helps to break down the LDL that forms thrombus in the blood vessels and transport it back to the liver, where the LDL is sequestered and eliminated from the body or stored in the form of lipid cells.

Testing for HDL-C is done to evaluate the patient's cardiovascular health, including their risk of heart disease. Good cholesterol, or HDL-C, is linked to a decreased risk of coronary heart disease events. The ratio of HDL-C to non-HDL cholesterol may be readily computed by the physician by measuring both total cholesterol and HDL-C in the same blood sample, which is vital for evaluating the patient's cardiovascular health.

The aging population demographic, sedentary lifestyle, and change in eating habits in the modern world are expected to increase the risk of cardiovascular disease incidence.

For instance, American Heart Association, Inc. states that around 18 million deaths globally are attributed to cardiovascular disease (CVD), with significant differences between high- and low-income countries (HICs) and LMICs. LMICs bear a disproportionate amount of the global burden of cardiovascular diseases (CVDs), accounting for 80% of all cardiovascular deaths globally.

In addition, as per the National Heart Foundation of Australia, one in six Australians is living with a cardiovascular disease accounting for nearly 4.5 million cases, which represent 18% of the total Australian population. In addition, more than 1500 hospital admissions and 24% of all deaths in Australia are attributed to CVD.

As this trend is expected to rise, the demand for preventative health measures is expected to rise that include timely heart health monitoring, is expected to create a huge demand for HDL cholesterol testing kits in the forecast period.

Restraints

The high cost of HDL cholesterol kits is one of the restraining factors that may hinder market growth. This can be an economic burden to small-scale health centers and clinics with low operational budgets. In addition, the lack of awareness among patients especially those living in rural areas regarding the importance of regular cholesterol checkups is another factor that may restrain the market growth.

Segment Analysis

The global HDL cholesterol kits market is segmented based on product type, modality, end-users, and region.

The colorimetry based kits in the type segment accounted for approximately 56.4% of the global HDL cholesterol kits market share

HDL cholesterol is routinely evaluated together with total cholesterol, LDL cholesterol, and triglycerides to track each patient's unique risk of developing cardiovascular disease. The most popular method for measuring HDL cholesterol is enzymatic colorimetric techniques, the gold standard for lipid analysis of this kind. Since the development of color is the endpoint in this process, the intensity, and other parameters can be estimated by employing ultraviolet-visible spectroscopy at 500 nm. This is a widely accepted method due to its simplicity, cost-effectiveness, sensitivity, and specificity. Moreover, many HDL detection kits manufactured by prominent players utilize the colorimetric method.

Geographical Analysis

North America is expected to dominate the market with a 43.2% share in the global HDL cholesterol kits market

North America is expected to dominate the market due to its well-advanced healthcare infrastructure, state-of-the-art diagnostic centers, clinical laboratories, etc. Moreover, the the major high-income countries in the region the U.S. and Canada are well-known for their investments in the healthcare industry

For instance, Laboratory Corporation of America Holdings has nearly 2,000 centers spanning across the U.S. providing several diagnostic testing services including the cholesterol panel. Quest Diagnostics, another prominent diagnostic service provider has over 2,000 of its patient service centers and nearly 7,400 patient access points in the U.S.

This well-established network of clinical laboratories provides testing services all across the nation making the service easily accessible by all the population.

Moreover, the region is known for its high prevalence of cardiovascular-related events. As per the American Heart Association's heart disease and stroke statistics 2024 update, nearly 222.4 per 100,000 patients age-adjusted death rate attributable to CVD, and nearly 25.5% of the U.S. adult population have their LDL-cholesterol greater than 130mg/dL. Low-density lipoprotein (LDL) is the major culprit in the majority of cardiovascular conditions such as ischemia, atherosclerosis, and stroke. Moreover, nearly 9.7 million people in the U.S. have undiagnosed diabetes, 29.3 million people have been diagnosed with diabetes and 115.9 million people are at risk of pre-diabetes.

Considering the high prevalence of cardiovascular indications, and the well-established healthcare systems combined with top-tier clinical laboratories providing HDL testing services the demand and the sales volume of HDL cholesterol kits is far higher in the North American region. In addition, most market leaders have established a stronghold market position in the region, making the kits easily available to healthcare facilities. All these factors are expected to be contributing to the region's dominance in the global market for HDL cholesterol kits.

Covid-19 Analysis

The Covid-19 pandemic had a significant impact on the market of HDL cholesterol kits. During the pandemic, the global supply chain has been disrupted due to imposed restrictions on movement and lockdowns. The restriction in movement has reduced the hospital and clinical laboratory visits by the patients, which is anticipated to have resulted in decreased HDL cholesterol testing volumes. Moreover, the clinical labs and hospitals were majorly focused on providing testing services to the Covid-infected patients which is anticipated to have resulted in decreased testing volume.

For instance, a study conducted in the Mass General Brigham (MGB) which is a large integrated healthcare system serving Massachusetts and its neighboring states, has found a 39.2% decline in weekly cholesterol tests from 6,361 in 2019 to 3,867 in 2020, with the greatest reductions occurring during the first wave of the pandemic accounting for 92% reduction in the testing volume.

Market Segmentation

By Type

Colorimetry Based Kits
Fluorometry Based Kits
Precipitation Based Kits
Others

By Sample Type

Serum
Plasma
Urine
Others

By End-Users

Hospitals
Specialty Clinics
Diagnostic Centers
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
South America
- Brazil
- Argentina
- Rest of South America
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Middle East and Africa

Competitive Landscape

The major players in the HDL cholesterol kits market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott, Merck KGaA, Randox Laboratories Ltd., SEKISUI Diagnostics, Abcam Limited., Diazyme Laboratories, Inc., Cell Biolabs, Inc. and DiaSys Diagnostic Systems GmbH among others.

Why Purchase the Report?

To visualize the global HDL cholesterol kits market segmentation based on type, sample type, end-users and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of HDL cholesterol kits market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global HDL cholesterol kits market report would provide approximately 62 tables, 55 figures, and 187 Pages.

Target Audience 2024

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Sample Type
3.3. Snippet by End-Users

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising prevalence of cardiovascular conditions
  - 4.1.1.2. Rising technological advancements
- 4.1.2. Restraints
  - 4.1.2.1. Lack of awareness and limited access to healthcare
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
7.2. Colorimetry Based Kits*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Fluorometry Based Kits
7.4. Precipitation Based Kits
7.5. Others

8. By Sample Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 8.1.2. Market Attractiveness Index, By Sample Type
8.2. Serum*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Plasma
8.4. Urine
8.5. Others

9. By End-Users

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
- 9.1.2. Market Attractiveness Index, By End-Users
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Specialty Clinics
9.4. Diagnostic Centers
9.5. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. The U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.5.1. Germany
  - 10.3.5.2. UK
  - 10.3.5.3. France
  - 10.3.5.4. Italy
  - 10.3.5.5. Spain
  - 10.3.5.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.5.1. Brazil
  - 10.4.5.2. Argentina
  - 10.4.5.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.5.1. China
  - 10.5.5.2. India
  - 10.5.5.3. Japan
  - 10.5.5.4. South Korea
  - 10.5.5.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. F. Hoffmann-La Roche Ltd
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Thermo Fisher Scientific Inc.
12.3. Abbott
12.4. Merck KGaA
12.5. Randox Laboratories Ltd.
12.6. SEKISUI Diagnostics
12.7. Abcam Limited.
12.8. Diazyme Laboratories, Inc.
12.9. Cell Biolabs, Inc.
12.10. DiaSys Diagnostic Systems GmbH (LIST NOT EXHAUSTIVE)